NCT01855854View on ClinicalTrials.gov

Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH

PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

August 31, 2015

Study Completion Date

January 7, 2016

Conditions
Adenocarcinoma of the Gastroesophageal JunctionEsophageal Carcinoma
Interventions
DRUG

Icotinib

Icotinib: 250 mg is administered orally three times per day, until disease progression or untolerable toxicity.

Trial Locations (1)

100021

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing

Sponsors
All Listed Sponsors
lead

Betta Pharmaceuticals Co., Ltd.

INDUSTRY

NCT01855854 - Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH | Biotech Hunter | Biotech Hunter